Drugs / ION269
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06673069 | Dec 2024 → Dec 2025 | Alzheimer disease, Down syndrome | Ionis Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06673069 ↗ |
| Route | Intrathecal | “Administered as intrathecal (IT) injection.” NCT06673069 ↗ |